Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson’s disease
Abstract. This study aimed to investigate the spatiotemporal changes in neuromelanin-sensitive MRI signal in the substantia nigra and their relation to clinica
Related Articles
RAB32 Ser71Arg in autosomal dominant Parkinson’s disease: linkage, association, and functional analyses
RAB32 Ser71Arg is a novel genetic risk factor for Parkinson’s disease, with reduced penetrance. The variant was found in individuals with Parkinson’s disease from multiple…
Extended interval dosing with ocrelizumab in multiple sclerosis – Frederik Novak, Hamza Mahmood Bajwa, Kamilla Østergaard, Jonas Munksgaard Berg, Jonna Skov Madsen, Dorte Aalund Olsen, Inga Urbonaviciute, Zsolt Illes, Morten Leif Stilund, Jeppe Romme Christensen, Stephan Bramow, Finn Sellebjerg, Tob
Background: This study investigates clinical and biomarker differences between standard interval dosing (SID) and extended interval dosing (EID) of ocrelizumab …
Genetics of immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis
Huang et al. examine how a person’s genetic make-up affects their immune response to Epstein-Barr virus and how this relationship affects risk for multiple
Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
Sánchez-Juan et al. reveal an association between serum GFAP levels and post-mortem tau pathology in patients with dementia, independent of amyloid deposit
Paraneoplastic Calmodulin Kinase‐Like Vesicle‐Associated Protein (CAMKV) Autoimmune Encephalitis
Annals of Neurology is a leading neurology journal from the American Neurological Association focusing on diseases of the human nervous system.
Cognitively healthy centenarians are genetically protected against Alzheimer’s disease
BACKGROUND Alzheimer’s disease (AD) prevalence increases with age, yet a small fraction of the population reaches ages > 100 years without cognitive decline. We studied…
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer’s disease trial
INTRODUCTION In trials of amyloid-lowering drugs for Alzheimer’s disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined pl…
Diversity, equity and inclusion in neurology
This Series highlights the importance of efforts to improve diversity, equity and inclusion (DEI) in the neurology community and in neurological care to …
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
Nature Medicine – An exploratory analysis of the 1-year clinical trial PASADENA in individuals with early-stage Parkinson’s disease suggests that prasinezumab might reduce motor signs…
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
Nature Medicine – An exploratory analysis of the 1-year clinical trial PASADENA in individuals with early-stage Parkinson’s disease suggests that prasinezumab might reduce motor signs…